Literature DB >> 10626521

Incidence of ceftriaxone-associated gallbladder pseudolithiasis.

F Papadopoulou1, S Efremidis, S Karyda, M Badouraki, E Karatza, C Panteliadis, K Malaka.   

Abstract

We prospectively evaluated the incidence of gallbladder pseudolithiasis in children treated with high doses of ceftriaxone for a variety of serious infections. We also monitored the time interval needed for this phenomenon to develop and resolve completely after initiation and cessation of treatment, respectively. Included in this study are 44 children treated with ceftriaxone 100 mg/kg/d divided into 2 equal intravenous doses and followed by serial abdominal sonography. Eleven children developed pseudolithiasis of gallbladder 2-9 d after initiation of ceftriaxone therapy. Six children (54.5%) developed this complication within the first 3 d. Lithiasis completely resolved 8-23 d after the end of treatment. In conclusion, pseudolithiasis of the gallbladder developed in 25% of sick children and completely resolved in all patients. Early development of this complication was not exceptional. It occurred in more than half of these children.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10626521     DOI: 10.1080/080352599750030077

Source DB:  PubMed          Journal:  Acta Paediatr        ISSN: 0803-5253            Impact factor:   2.299


  15 in total

1.  Acute necrotizing cholecystitis: a rare complication of ceftriaxone-associated pseudolithiasis.

Authors:  Sendia Kim; Kathleen M Gura; Mark Puder
Journal:  Pediatr Surg Int       Date:  2006-02-17       Impact factor: 1.827

2.  A symptomatic child with ceftriaxone-associated biliary pseudolithiasis.

Authors:  Naoki Kutuya; Yutaka Ozaki; Tadaharu Okazaki
Journal:  J Med Ultrason (2001)       Date:  2008-09-19       Impact factor: 1.314

3.  Ceftriaxone-induced pseudolithiasis: not just a theoretical risk.

Authors:  Lijia Fan; Perry Lau; Jeevesh Kapur; Sivaramakrishnan Venkatesh Karthik
Journal:  Singapore Med J       Date:  2017-11       Impact factor: 1.858

4.  Increased urinary calcium excretion caused by ceftriaxone: possible association with urolithiasis.

Authors:  Takahisa Kimata; Kazunari Kaneko; Masaya Takahashi; Masato Hirabayashi; Tomohiko Shimo; Minoru Kino
Journal:  Pediatr Nephrol       Date:  2011-10-27       Impact factor: 3.714

5.  Ceftriaxone associated urolithiasis in a child with hypercalciuria.

Authors:  V J Lozanovski; Z Gucev; V J Avramoski; I Kirovski; P Makreski; V Tasic
Journal:  Hippokratia       Date:  2011-04       Impact factor: 0.471

6.  Increasing urinary calcium excretion after ceftriaxone and cephalothin therapy in adults: possible association with urolithiasis.

Authors:  Alper Otunctemur; Emin Ozbek; Emre Can Polat; Mustafa Cekmen; Murat Dursun; Suleyman Sami Cakir
Journal:  Urolithiasis       Date:  2013-12-06       Impact factor: 3.436

Review 7.  Drug-Induced Kidney Stones and Crystalline Nephropathy: Pathophysiology, Prevention and Treatment.

Authors:  Michel Daudon; Vincent Frochot; Dominique Bazin; Paul Jungers
Journal:  Drugs       Date:  2018-02       Impact factor: 9.546

8.  Ceftriaxone-induced pseudolithiasis in children treated for perforated appendicitis.

Authors:  Hanna Alemayehu; Amita A Desai; Priscilla Thomas; Susan W Sharp; Shawn D St Peter
Journal:  Pediatr Surg Int       Date:  2014-01-28       Impact factor: 1.827

9.  Biliary pseudolithiasis secondary to ceftriaxone therapy.

Authors:  Syed Ahmed Zaki; Preeti Shanbag
Journal:  Indian J Pharmacol       Date:  2010-06       Impact factor: 1.200

10.  Management of cholelithiasis in Italian children: a national multicenter study.

Authors:  Claudia Della Corte; Diego Falchetti; Gabriella Nebbia; Marisa Calacoci; Maria Pastore; Ruggiero Francavilla; Matilde Marcellini; Pietro Vajro; Raffaele Iorio
Journal:  World J Gastroenterol       Date:  2008-03-07       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.